Method of drug design
AssigneeAlchemia Limited
InventorsGerald B. TOMETZKI, Wim F. MEUTERMANS, Johannes ZUEGG
Life of this patent
Estimating the term…
Abstract
The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1).
Claims24
1-20. (canceled)
A method of identifying biologically active compounds comprising:
- (a) designing a first library of compounds of formula 1 to scan molecular diversity wherein for each compound of the first library R2 and one of R1, R3, R4, and R5 as defined below are pharmacophoric groups and the remainder of R1, R3, R4, and R5 are non-pharmacophoric groups;
- (b) assessing the first library of compounds in one or more biological activity assay(s);
- and
- (c) designing a second library wherein for each compound of the second library the substituents R1 to R5 comprise the two pharmacophoric groups identified in step (b) and a third pharmacophoric group, and wherein the remainder of R1, R3, R4, and R5 are non-pharmacophoric groups,
- such that the/each component of the first and second library is a compound of formula 1:
- Z is sulphur, oxygen, NH, NRA or hydrogen, in the case where Z is hydrogen then R1 is not present;
- RA is selected from the set defined for R1, R3, R4, and R5, or wherein Z and R1 together form a heterocycle;
- X is oxygen or nitrogen;
- R2 is a pharmacophoric group independently selected from the group consisting of C2 to C20 alkyl, C2 to C20 acyl, wherein said acyl is not acetyl;
- C2 to C20 alkenyl, C2 to C20 alkynyl, C2 to C20 heteroalkyl, C5 to C20 aryl, C5 to C20 heteroaryl, C5 to C20 arylalkyl and C5 to C20 heteroarylalkyl, which is optionally substituted, and can be branched or linear, or wherein NH and R2 combine to form a heterocycle;
- R1, R3, R4, and R5 are each independently selected from
- (i) non-pharmacophoric groups consisting of H, methyl and acetyl, and
- (ii) pharmacophoric groups independently selected from the group consisting of C2 to C20 alkyl, C2 to C20 acyl, wherein said acyl is not acetyl;
- C2 to C20 alkenyl, C2 to C20 alkynyl, C2 to C20 heteroalkyl;
- C5 to C20 aryl, C5 to C20 heteroaryl, C5 to C20 arylalkyl and C5 to C20 heteroarylalkyl, which is optionally substituted, and can be branched or linear, or wherein X and the corresponding R moiety, R3 to R5 respectively, combine to form a heterocycle.
Dependencies are inferred from the claim text.